Since MEK/ERK reactivation during resistance induces MYC (a convergent point in multiple resistance pathways)28, which is efficiently blocked by targeting ABL1/2, and ABL1 mRNA is upregulated during resistance in primary melanomas, we examined the clinical significance of our findings by testing whether ABL1 and MYC expression are linked in patient samples. Here, MAP2K7 is linked to melanoma.